Your browser is no longer supported. Please, upgrade your browser.
CFRX ContraFect Corporation daily Stock Chart
ContraFect Corporation
Index- P/E- EPS (ttm)-3.50 Insider Own15.90% Shs Outstand15.33M Perf Week-8.91%
Market Cap159.89M Forward P/E- EPS next Y-1.36 Insider Trans0.00% Shs Float11.44M Perf Month21.22%
Income-32.00M PEG- EPS next Q-0.41 Inst Own35.00% Short Float13.88% Perf Quarter-12.79%
Sales- P/S- EPS this Y68.80% Inst Trans73.76% Short Ratio4.47 Perf Half Y-39.62%
Book/sh0.56 P/B11.32 EPS next Y13.90% ROA-128.10% Target Price- Perf Year33.19%
Cash/sh0.66 P/C9.63 EPS next 5Y20.80% ROE-340.40% 52W Range2.69 - 13.40 Perf YTD2.14%
Dividend- P/FCF- EPS past 5Y47.50% ROI- 52W High-52.46% Beta1.09
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low136.54% ATR0.63
Employees24 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)49.05 Volatility9.98% 10.00%
OptionableYes Debt/Eq0.00 EPS Q/Q-133.90% Profit Margin- Rel Volume0.21 Prev Close6.34
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume355.06K Price6.37
Recom1.80 SMA20-5.27% SMA504.06% SMA2005.11% Volume3,961 Change0.47%
Jun-09-20Initiated Mizuho Buy $12
Jun-09-20Initiated Cantor Fitzgerald Overweight $15
Jul-28-16Initiated Piper Jaffray Overweight
Jul-22-16Downgrade Maxim Group Buy → Hold
Mar-15-16Reiterated Maxim Group Buy $8 → $7
Dec-31-15Reiterated Maxim Group Buy $16 → $9
Jul-03-20 08:48AM  
Jun-18-20 10:56AM  
Jun-17-20 07:30AM  
Jun-15-20 07:30AM  
Jun-10-20 01:46PM  
May-29-20 06:43AM  
May-26-20 07:30AM  
May-22-20 07:10AM  
May-21-20 10:59PM  
May-15-20 07:30AM  
May-11-20 07:30AM  
Apr-21-20 07:00AM  
Mar-30-20 05:00AM  
Mar-23-20 06:15AM  
Mar-21-20 09:01AM  
Mar-18-20 07:00AM  
Mar-04-20 07:00AM  
Feb-24-20 07:00AM  
Feb-18-20 03:45PM  
Feb-04-20 07:00AM  
Feb-03-20 07:00AM  
Jan-27-20 07:00AM  
Jan-22-20 07:00AM  
Jan-21-20 05:00AM  
Jan-13-20 08:00AM  
Jan-10-20 07:00AM  
Jan-06-20 05:30PM  
Jan-04-20 07:30AM  
Dec-20-19 10:56AM  
Dec-18-19 07:00AM  
Dec-17-19 09:25AM  
Dec-16-19 07:30AM  
Dec-10-19 08:46AM  
Dec-09-19 04:03PM  
Nov-29-19 09:00AM  
Nov-18-19 08:05AM  
Nov-12-19 07:00AM  
Nov-05-19 07:00AM  
Oct-07-19 09:05AM  
Oct-02-19 07:00AM  
Oct-01-19 05:29PM  
Sep-26-19 07:00AM  
Sep-04-19 05:07PM  
Aug-28-19 07:00AM  
Aug-16-19 10:45AM  
Aug-09-19 07:00AM  
Jul-01-19 09:13AM  
Jun-20-19 11:13AM  
Jun-19-19 01:08PM  
Jun-17-19 05:00PM  
Jun-07-19 09:27AM  
Jun-06-19 07:00AM  
Jun-03-19 07:00AM  
May-31-19 07:00AM  
May-20-19 10:15AM  
May-10-19 07:19AM  
May-08-19 07:00AM  
Apr-30-19 10:30AM  
Apr-16-19 05:15AM  
Apr-13-19 09:38AM  
Apr-12-19 10:08AM  
Apr-08-19 07:00AM  
Apr-04-19 07:00AM  
Apr-02-19 07:00AM  
Mar-21-19 07:00AM  
Mar-20-19 10:30AM  
Mar-14-19 08:01AM  
Mar-13-19 07:00AM  
Mar-04-19 07:00AM  
Feb-25-19 07:00AM  
Feb-13-19 07:00AM  
Jan-17-19 10:00AM  
Jan-09-19 09:45AM  
Jan-07-19 07:00AM  
Dec-23-18 10:22AM  
Dec-20-18 05:00PM  
Nov-19-18 07:00AM  
Nov-16-18 07:50AM  
Nov-12-18 09:15AM  
Nov-08-18 09:59AM  
Nov-01-18 07:00AM  
Oct-22-18 05:00PM  
Sep-25-18 07:00AM  
Sep-24-18 09:30AM  
Sep-20-18 05:00PM  
Sep-06-18 08:30AM  
Aug-29-18 05:30PM  
Aug-14-18 05:00PM  
ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin, which has completed Phase II clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible; and CF-404, a combination of monoclonal antibodies (mAbs), which is in preclinical trial stage for the treatment of life-threatening seasonal and pandemic influenza infections. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting gram-negative pathogens; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Messinger MichaelChief Financial OfficerDec 13Buy0.375,0001,85019,091Dec 16 06:28 AM
Sucoff CaryDirectorDec 13Buy0.3950,00019,50062,000Dec 16 06:26 AM
Low David N.DirectorDec 13Buy0.43300,000129,000370,550Dec 16 06:21 AM